Prevalence of the C536T mutation in the tissue factor pathway inhibitor (TFPI) gene among patients with venous thromboembolic disease

Thrombosis and Haemostasis

Volumn 85, Issue 5, 2001, Pages 938-939

  Paciaroni, K ^a   Rossi, E ^a   Bazzan, M ^a   Ireland, H ^a   De Stefano, V ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ADOLESCENT; ADULT; AGED; ANTITHROMBIN III DEFICIENCY; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; INFANT; ITALY; LETTER; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN DISEASE;

EID: 0035004624     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615774     Document Type: Letter

References (6)

1. The lipoprotein-associated coagulation inhibitor that inhibits factor Xa: Insight into its possible mechanism of action
2. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L] TFPI
3. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis
4. The C536T transition in the tissue factor pathway inhibitor gene is not a common cause of venous thromboembolic disease in the UK population
5. The TFPI 536C → T mutation is not associated with increased risk for venous or arterial thrombosis
6. Prevalence of mild hyperhomocysteinemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease